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High-dose chemotherapy (HD-CT) has a role in the potentially curative treatment of several tumours. The relative efficacies of the
different regimens have not been studied in comparative trials, but it is clear that toxicities differ significantly between them. We
analysed the immediate and long-term toxicity in the first 100 consecutive patients treated with the CTC regimen
(cyclophosphamide 6000mgm
 2, carboplatin 1600mgm
 2 (or 20mgml
 1min under the curve (AUC)) both as daily 1h infusion,
thiotepa 480mgm
 2 as twice daily 30min infusion, all divided over 4 consecutive days) followed by peripheral blood progenitor cell
reinfusion (PBPC-Tx). Most patients had high-risk (n¼86) or metastatic (n¼4) breast cancer, or a germ cell tumour (n¼8). Two
patients (with a medulloblastoma and an aesthesioneuroblastoma, respectively) received CTC as off-protocol salvage regimen. The
main toxicity was bone marrow suppression. Most patients had PBPC-Tx with granulocyte colony-stimulating factor (G-CSF), and the
median time to neutrophil count 500 10
6l
 1 and platelet count 420 10
9l
 1 without transfusion independence was 10 (range
8–25) and 13 (8–60) days, respectively. The toxic death rate was 1%. Other frequent toxicities were neutropenic fever requiring
antibiotics (n¼65), central catheter-related infection (n¼12) or a bleeding episode (n¼48), mostly epistaxis (n¼26). Reversible
cardiac toxicity was seen in six patients and pulmonary events occurred in seven patients (infection (n¼6), embolism (n¼1)). Grade
3–4 gastrointestinal toxicity was frequent: nausea and vomiting 55%, diarrhoea 28% and mild liver toxicity (transaminase elevations)
9%. One patient pretreated with cisplatin had a kidney transplantation 8 years after HD-CT. Late complications included reversible
radiation pneumonitis (n¼12) and chronic heart failure (n¼2). We found five second solid malignancies and two myelodysplasias. In
conclusion, the CTC regimen is associated with a moderate, mainly reversible, toxicity. Future studies need to compare the efficacy
and toxicity of the different HD-CT regimens.
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Many thousands of patients with solid tumours and lymphomas
have received high-dose chemotherapy (HD-CT) with autologous
blood progenitor cell rescue in the past decades (Antman et al,
1997; Rosti and Ferrante, 2001). While this treatment modality has
been accepted as the standard of care in the salvage setting for
certain malignant lymphomas and germ cell tumours, its role in
the management of frequently occurring tumours such as breast or
ovarian cancer is still unclear, as the results of randomised phase
III studies are still pending. For high-risk breast cancer, for
example, preliminary data have now been reported from nine
studies involving over 3000 patients (Rodenhuis, 2000). The first
statistically meaningful analyses of these studies and of yet
unreported studies would hopefully be evaluated in the 2005
Oxford Overview.
While the relative efficacies of the different high-dose regimens
have not been studied in comparative trials, it is clear that toxicity
differs, and that certain regimens are associated with considerable
morbidity and even with mortality. The STAMP-I regimen, for
example, which incorporates cisplatin, cyclophosphamide and
BCNU, is associated with a 12% mortality rate, mainly resulting
from (BCNU-related) lung toxicity (Antman et al, 1997; Rosti and
Ferrante, 2001). The widely employed STAMP-V regimen, a
combination of cyclophosphamide, thiotepa and carboplatin
(CTC), has been reported to be well tolerated (Antman et al,
1992). STAMP-V has been employed in several large randomised
studies in breast cancer (Bergh et al, 2000; Stadtmauer et al, 2000),
none of which showed a (progression-free) survival advantage for
the patients receiving this treatment.
A regimen similar to STAMP-V, called CTC, has been reported
from our institution (Rodenhuis et al, 1992). It contains the same
agents as STAMP-V, but the carboplatin dose is twice as high and
the agents are administered as short-term infusions rather than as
continuous infusions. CTC has been used in several randomised
and nonrandomised studies in high-risk (van der Wall et al, 1995;
Rodenhuis et al, 1996, 1998, 1999, 2000; Schrama et al, 2002) and
in stage IV breast cancer (Schrama et al, 2001; De Gast et al, 2002)
and, moreover, in the salvage therapy of germ cell cancer
(Rodenhuis et al, 1996, 1999).
Since CTC is associated with only moderate toxicity and re-
cent results by our group indicate that this toxicity can even be
reduced further when ‘Therapeutic Drug Monitoring’ is employed
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l(Huitema et al, 2001), we believe that future studies will need to
compare the efficacy and toxicities of CTC to that of other high-
dose regimens. To facilitate the design of this type of comparison,
we have analysed the immediate and long-term toxicities of CTC in
the first 100 consecutive patients who received this regimen in our
institution. For this patient group, a median follow-up of almost 5
years is available with a lead follow-up of over 11 years (137
months).
PATIENTS AND METHODS
Patients
We analysed the first 100 consecutive patients treated with the
high-dose CTC chemotherapy regimen, who were treated between
1989 and 2000 in our institution. The CTC regimen is a widely used
regimen and besides patients with breast cancer we analysed even
patients with germ cell tumours and other tumours to study
whether the pretreatment was important for toxicity.
Of these patients, 86 had high-risk breast cancer and were
included in one of two randomised adjuvant chemotherapy studies
(Rodenhuis et al, 1998, 2000). Four patients with metastatic breast
tumours were treated in a pilot study. Six of eight patients with
germ cell tumours were treated in another previously published
study (Rodenhuis et al, 1999). The two patients with either
aesthesioneuroblastoma or a medullablastoma received the regi-
men as part of an off-protocol salvage regimen (Table 1). Written
informed consent was obtained from all patients at enrolment in
the studies, and the Committee on Medical Ethics of The
Netherlands Cancer Institute approved all these studies.
Treatment regimen
Induction therapy regimen and collection of progenitor cells The
treatment regimens are summarised in Table 2. The procedures of
bone marrow harvesting and leucoytaphoris have been described
previously (van der Wall et al, 1995; Rodenhuis et al, 1996, 1998,
1999, 2000).
High-dose regimen All patients received the same high-dose
regimen consisting of one cycle of cyclophosphamide 6gm
 2 as a
daily 1h infusion, thiotepa 480mgm
 2 as a twice daily 30min
infusion, and carboplatin 1600mgm
 2 (in case of abnormal
kidney function, the carboplatin dosage was based on an area
under the curve (AUC) of 20mgml
 1min) as a daily 1h infusion,
all divided over 4 consecutive days. Mesna (500mg) was
administered six times daily for a total of 36 doses, starting 1h
prior to the first cyclophosphamide infusion. The peripheral blood
progenitor cell reinfusion (PBPC-Tx) was performed 2 days after
the end of the chemotherapy. The prophylactic use of antiemetics
and antibiotics of the separate studies have been described
elsewhere (Rodenhuis et al, 1992, 1996, 1998, 1999, 2000; van der
Wall et al, 1995). Briefly, all patients received antiemetics
prophylactically, consisting of dexamethasone and serotonin
antagonist and/or metoclopramide. Antibiotic prophylaxis con-
sisted of oral ciprofloxacin 1000mg (divided over two daily gifts)
and oral amphotericin B (2000mg divided over four daily gifts).
Cultures of throat, nose, stool or perineum and central venous
catheter (CVC) were performed twice a week. In the first CTC
courses, cultures of the CVC were performed every day. As
prophylaxis for infection with Gram-positive bacteria, patients
either received penicillin G 1 10
6IU q.i.d. or roxithromycin
150mg b.i.d. orally. The large majority of patients received
acyclovir either orally or intravenously to prevent herpes
reactivation. In case of fever, antibiotic treatment was started
empirically, either with vancomycin 500mg q.i.d. and ceftazidime
2g three times daily or with teicoplanin 400mg and ceftriaxone 2g
once daily. All but 15 patients received daily granulocyte colony-
stimulating factor (G-CSF) injections from the day of transplanta-
tion until the WBC count exceeded 5 10
9l
 1. Irradiated
leucocyte-free red blood cells and platelets were given to maintain
haemoglobin and platelet count above 5.5mmoll
 1 and
10 10
9l
 1, respectively.
Toxicity
The toxicity data were extracted from patient records and from
databases associated with various studies in which the patients had
participated. The toxicity was scored before start of the induction
regimen, during the CTC chemotherapy, after each course and at
the follow-up date. Toxicity was graded according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC) (NCI,
1998). Long-term toxicity was also scored with the NCI-CTC
criteria, but because most toxicities were infrequent, they were
registered in a dichotomous or descriptive way. Long-term toxicity
was defined as toxicity still lasting or appearing more than 1 year
after high-dose treatment.
RESULTS
We have analysed the toxicity of CTC in 100 consecutive patients
treated between 1989 and 2000 who received a PBPC-Tx in our
institution. At the time of the evaluation, 63 of these 100 patients
were still alive. The median follow-up time of all patients was
almost 5 years, with a lead follow-up of 137 months.
Bone marrow recovery
Predictably, the main toxicity of HD-CT was bone marrow
suppression. All patients had periods of absolute neutropenia
and required platelet and red cell transfusions. As the duration of
the neutropenic period and thrombocytopenia is significantly
reduced after peripheral stem cell reinfusion with G-CSF compared
Table 1 Patient characteristics
Characteristics All patients
No. of patients 100
Median age (years) (range) 46 (21–57)
Type of tumour
Germ cell 8
Breast cancer
Stage II–III 86
Stage IV 4
Asthesioneuroblastoma 1
Medulloblastoma 1
Prior to chemotherapy
a
Cisplatin-based 8
Anthracyclin-based 1
Prior to surgery
Mastectomy 73
Breast-conserving surgery 15
Orchidectomy 9
Other 5
b
Prior to radiotherapy
Breast/parasternal 2
Brain 1
Other 1
aChemotherapy before enrolment in the treatment protocol.
bTwo patients had a
sternotomy, two patients had a laparotomy and one patient had a craniotomy, all
because of metastatic disease.
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the bone marrow recovery were analysed separately for these
patient groups (Table 3).
Most patients had PBPC-Tx with G-CSF and the median time to a
neutrophil granulocyte count of 4500 10
6l
 1 was 10 days (range
8–25). The median time to platelet transfusion independence
(defined as platelets 420 10
9l
 1 without platelet transfusion) was
13 days (range 8–60). The patients required a median of 3 (range
1–9) platelet transfusions and 6U of red cells (range 2–35). Two
patients had an excessive need of red blood cell transfusions: one
patient developed a large haematoma in the abdominal wall and
ultimately died of multiorgan failure (see below). The second
patient required 31U of red cells because of haemolysis due to a
previously undiagnosed hereditary spherocytosis and was later
treated successfully with a splenectomy. The patients with combined
ABMT and PBPC-Tx had comparable results. As expected, the
patients receiving ABMT-only repopulated later (neutrophil count
4500 10
6l
 1 with G-CSF (n¼4) on day 18 (range 14–36) and
without G-CSF (n¼5) on day 27 (21–29)), respectively, and the
median times to platelet transfusion independence were 21 days
(range 13–27) and 28 days (27–38), respectively.
Infectious complications
In total, 83 patients developed fever X381C for one or more days
(median duration 5 days (range 1–18)) in the neutropenic period
following HD-CT (Table 3). Most of these patients (n¼65) had
fever of unknown origin. Five had clinical and radiological signs of
pneumonia, but in only one of them a causative microorganism
(parainfluenza virus) could be isolated. In this patient, transferal to
the intensive care unit was necessary because of respiratory
distress. In 12 patients, blood cultures from the indwelling
intravenous catheter became positive, usually for coagulase-
negative Staphylococci. The amount of positive blood cultures
could be relatively high, because in the first courses cultures were
performed every day instead of twice a week later on. Six more
patients had the following documented infections: one patient had a
positive blood culture with a Streptococcus pneumoniae without
respiratory symptoms. In a second patient, pulmonary tuberculosis
was diagnosed on day 8 after PBPC-Tx. A third patient threw up an
ascaris worm and received mebendazole for 3 days. A fourth patient
had a symptomatic and possibly invasive Candida infection of the
mouth. In a fifth patient, a pansinusitis was diagnosed from which
Pseudomonas aeruginosa was cultured. The sixth patient developed
multiorgan failure, possibly resulting from infection of a large
haematoma with coagulase-negative Staphylococci (see below).
Bleeding episodes
Bleeding episodes during low platelet counts were frequent (48%),
but were mild and never life-threatening: most frequent were
epistaxis (26%) and vaginal bleeding related to the menstrual cycle
(12%).
Non-haematological toxicity
The organ toxicities during the CTC courses and the period
thereafter are summarised in Table 4. Nausea and vomiting was
seen in all patients, despite intensive antiemetic therapy. Many
patients (n¼42) had WHO grade 3–4 nausea and/or vomiting
starting on the third day of the CTC course, with a median
duration of 8 days. Diarrhaea grade 3–4 was found in 28% of the
patients, median starting on day 3 after transplantation and lasting
for a median of 5.5 days. Mucositis was usually mild, but grade 3–
4 toxicity was found in 19 patients. Skin rash was frequently seen
(grade 3–4 toxicity in 21 patients, median starting on day 7 after
transplantation) and usually coincided with the administration of
broad-spectrum antibiotics.
Symptomatic tinnitus and hearing loss were noted in 12
patients, but only five patients had grade 3–4 toxicity tinnitus
and/or hearing loss. At 2 months after transplantation, nine
patients (four patients with cisplatin pretreatment) still had
symptomatic high-frequency hearing loss and problems with
conversation and background noise, eight patients (five patients
with cisplatin pretreatment) had intermittent tinnitus and one
patient in the breast cancer group still had continuous tinnitus.
Audiograms were not routinely performed. Hearing aids were
never required. At long-term follow-up, only one patient had
symptomatic high-frequency loss and two patients still had
symptomatic tinnitus, all in the breast cancer group.
Neuropathy was mild (limited to paresthesias in hands and feet)
and occurred in five patients during chemotherapy. After 2
months, nine patients had slight sensory and two patients
moderate sensory neuropathy. Neuropathy was more common in
the patients with germ cell tumours pretreated with cisplatin than
in the breast cancer patients (55 vs 7%).
Renal toxicity (defined as a rise of serum creatinine of 1.5   the
normal value (XCTC grade 2 toxicity)) was seen in 12 patients and
was at least partially reversible in most cases within 2 months
(Tables 5 and 6). However, seven patients kept a permanent mild
elevation of the serum creatinine (CTC grade 1). Three of these
patients had a germ cell tumour and had received prior treatment
with cisplatin, and all of them already had a creatinine elevation
before high-dose therapy. One patient with a germ cell tumour
who developed severe kidney toxicity, was found to have a
hypoplastic left kidney and nephrosclerosis on the right side, 8
years after HD-CT. Nephrotoxic chemotherapy was thought to be
the cause of these problems. He underwent a successful kidney
transplantation 8 years after transplantation.
Mild hepatotoxicity (Table 5) was seen in all patients and
consisted mainly of a transient rise in ALAT and ASAT on the day
of transplant (day 0). A total of 36 patients also had a rise of
Table 2 Treatment regimens
No. of patients Treatment regimen
Germ cell tumour 8 Carboplatin/etoposide
a
Breast cancer 90
Stage II–III
Adjuvant 55 5 FE90C
b-CTC-RT and tamoxifen
Neoadjuvant 31 3 FE120C
b-surgery-1 FE120C-CTC-RT and tamoxifen
Stage IV 4 Methotrexate and/or anthracyclin-containing regimen-CTC
Asthesioblastoma 1 Cisplatin/ifosfamide/etoposide-CTC
Neuroblastoma 1 2 EVAIA/2 BEP/1 ifosfamide/etoposide-CTC
aTwo courses carboplatin 800mgm
 2 day 1 and etoposide 500mgm
 2 days 1–3.
bFE90C¼5-fluorouracil 500mgm
 2,
epirubicin 90 or 120mgm
 2 and cyclophosphamide 500mgm
 2 all on day 1.
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lbilirubin, of alkaline phosphatase (median on day 4) and of
gamma GT (median on day 2). In all patients, the liver functions
normalised in 1–2 weeks.
Mild haemorrhagic cystitis (WHO grade 2) was seen in one
patient between days 7 and 11 after transplant during thrombo-
cytopenia. This did not lead to significant haemorrhagic or
haemodynamic complications.
Some degree of cardiac failure during the CTC regimen
was observed in six patients and was completely reversible in all
cases. All patients developed the first symptoms between days 3
and 8 after transplantation. Symptoms consisted of cardiomegaly
(n¼5), tachycardia (n¼4), pleural effusion (n¼2), peri-
cardial effusion (n¼2) or electrocardiogram changes (n¼3).
All six patients were treated with furosemide and oxygen as
needed. One patient was additionally treated with low-dose
dopamine during a week and a further patient needed nitroglycer-
in sublingually.
Seven patients developed pulmonary abnormalities, six with
breast cancer and one with a germ cell tumour. The symptoms
(dyspnoea, cough and fever) appeared between the second day of
the HD-CT until 17 days after transplantation. One patient had a
documented parainfluenza pneumonitis and four patients were
thought to have a pulmonary infection without identification of a
microorganism. As mentioned previously in this paper, one patient
reactivated previously unrecognised pulmonary tuberculosis. One
patient was diagnosed to have pulmonary embolism and started
with anticoagulant therapy. Pleural effusion without cardiac
toxicity was seen in one patient possibly due to cyclopho-
sphamide-related toxicity.
All premenopausal female patients became postmenopausal
after HD-CT. Psychologic toxicity has been described elsewhere
(Schagen et al, 2001).
Toxic death
One toxic death (1%) was seen in the high-risk breast cancer group
(Rodenhuis et al, 1998). This patient died at day 23 after HD-CT of
respiratory distress and multiorgan failure. This patient had been
treated with anticoagulant therapy because of thrombosis of the
Table 3 Bone marrow recovery
PBPC-Tx +G-CSF (range) PBPC-Tx (range) ABMT (range) ABMT +G-CSF (range)
No. of patients 81 10
a 54
Type of tumour
Breast cancer 76
Adjuvant 10
Advanced disease 2
Germ cell 1 1 1
Other 2 4 3
Day
b neutrophil granulocyte count 4500
c 9 (8–20) 18.5 (11–28) 27 (21–29) 18 (14–36)
Day neutrophil granulocyte count 41000
c 10 (8–20) 20 (17–34) 31 (16–36) 19.5 (16–39)
Day platelets
450 18 (9–60) 23 (14–39) 27 (2–38) 52 (37–55)
4100 28 (12–120) 25.5 (18–41) 40 (31–56) 53 (44–62)
Time to platelet transfusion independence
d 13 (8–60) 16 (10–28) 21 (13–27) 28 (27–38)
Day of discharge
e 13 (10–35) 16.5 (13–19) 20 (17–33) 32 (20–54)
No. of CD34 cellsl
 1 (10
6kg
 1) 9.1 (0.7–35) 10.3 (1.1–12.3)
No. of CFU-GM (10
4kg
 1) 465 (264–950) 207 (117–404)
Day fever4
381C 5 (0–18) 3 (0–6) 8 (1–16) 4.5 (0–12)
391C 2.5 (0–10) 2 (0–4) 3.5 (0–11) 2.5 (0–11)
No. of transfusions
Platelets (occasions) 3 (1–9) 2.5 (2–8) 7 (2–9) 5 (2–9)
Red blood cells (units) 6 (0–35)
f 6 (4–10) 12 (5–22) 16 (13–22)
Infections
Documented infections 4 1 1 0
Catheter-related infections 9 0 1 2
Suspected infections 58 4 3 0
Bleeding episode (all) 20 2 0 4
Epistaxis 7 2 3
Vaginal bleeding 3
Haematemesis 2
Haematuria 2
Gingiva bleeding 2
Haematomas 2
Other 2 1
Toxic death 1
PBPC-Tx¼peripheral blood progenitor cell transplantation.
aIn two patients G-CSF was started on day 13 after transplantation.
bDay 0 is day of PBPC-Tx.
cNeutrophil
granulocyte count 10
6l
 1.
dTime until platelets are 420 10
6 without platelet transfusion.
eDay 0 is the day of stem cell or bone marrow reinfusion.
fTwo patients needed
many units of red cells: one patient with a hereditary spherocytosis and one patient with an expanding hematoma.
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lCVC. The coagulation parameters had been normal before the start
of anticoagulant therapy. The oral anticoagulation therapy
(coumarins) was discontinued before high-dose therapy and low-
dose heparin subcutaneously was begun. At 4 days after stopping
coumarins, she spontaneously developed an expanding haemato-
ma in the abdominal wall. Laboratory investigations showed a
prolonged activated partial prothrombin time (APTT), which
could not be explained by the coagulation therapy. Surgery was
performed in an effort to localise and stop the bleeding, but this
was not successful. She went on to develop severe mucositis and an
interstitial pneumonia. No microorganisms were detected at
broncho-alveolar lavage. She eventually developed multiorgan
failure and the blood/urine/mouth cultures became positive for
coagulase-negative Staphylococci despite adequate antibiotic
treatment (teicoplanin and later vancomycin). At autopsy, no
viable tumour was found but the findings indicated a respiratory
distress syndrome and coagulase-negative Staphylococci could still
be cultured from the lung.
Late complications
The long-term toxicities are summarised in Table 6. Nephrotoxi-
city was seen in seven patients, consisting of a persisting elevation
of creatinine (4130mmoll
 1). One of these patients, previously
treated with cisplatin, developed end-stage renal failure (due to a
hypoplastic left kidney and nephrosclerosis of the right kidney)
and underwent a successful kidney transplantation, 8 years after
PBPC-Tx.
In all, 11 patients with breast cancer who received radiation
therapy following HD-CT developed signs of a radiation pneumo-
nitis. All responded readily to corticosteroids. One additional
patient had haemoptysis due to a vascular malformation in the
lung 4 years after HD-CT and radiotherapy on the mediastinal
tumour. He was treated with embolisation and later underwent a
lobectomy.
Three patients in the breast cancer group had long-term
ototoxicity (symptomatic high-frequency loss (n¼1), persisting
tinnitus (n¼2)), but no patient including those pretreated with
cisplatin had symptomatic hearing deficits. Neuropathy was seen
in nine patients, both in the germ cell (n¼2) and in the breast
cancer group (n¼7). Only one myocardial infarction was seen, not
exceeding the number expected for a normal population. Two
patients in the breast cancer group, both in the group treated with
conventional fluoruracil epirubicin cyclophosphamide (FEC)
courses, developed symptomatic cardiac failure 7 and 3 years
after HD-CT, respectively. The decline in ejection fraction was
thought to be due to the combination of chemotherapy and
radiotherapy. At the time of follow-up, both patients were still
treated with angiotensin-converting enzyme inhibitors and diure-
tics with good result.
Irreversible alopecia, which is sometimes seen after multiple
cycles of high-dose CTC, never occurred. Herpes zoster infection
was seen in 19 patients, all breast cancer patients. This was a rather
late complication with a median of 254 days after transplantation
Table 4 Acute toxicity of CTC
Toxicity Grade (CTC) No. of patients Median day start Median day end
All patients 100
Nausea and vomiting 3 or 4 55  36
Diarrhoea 3 or 4 28 0 11
Mucositis 3 or 4 19 2 11
Rash 3 or 4 21 7 13
Ototoxicity
Hearing loss 1 or 2 10 3 14
3o r4 3
Tinnitus 1 or 2 10 5 15
3o r4 3
Neuropathy 1 or 2 5 28 36
3o r4 0
Haemorrhagic cystitis 1 or 2 1 7 11
3o r4
Cardiotoxicity 1 or 2 3 6 12
3o r4 3
Pulmonary toxicity 1 or 2 5 8 15
3o r4 2
Day 0 is the day of transplantation. CTC was given from day  6 through  3.
Table 5 Liver and renal toxicity of high-dose chemotherapy
All patients Day of peak value (median)
Alkaline phosphatase
p5 normal value 17 4
X5 normal value 1
ASAT
p5 normal value 80 0
X5 normal value 9
ALAT
p5 normal value 72 0
X5 normal value 7
Bilirubin
p3 normal value 35 4
X3 normal value 1
Creatinine
p3 normal value 32 10
X3 normal value 10
Day 0 is day of PBPC-Tx.
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l(range 28–1060). Four patients had herpes simplex infections,
three of them had an anal herpes infection and one patient had an
oral herpes infection.
Second tumours
We found seven second solid neoplasms (Table 7). Two breast
cancer patients had benign tumours: a tubular adenoma of the
colon and a cervical polyp of the uterus, 5 and 7 years after
treatment, respectively. Most tumours were skin tumours. One
patient had both a melanoma and a squamous cell carcinoma
located at the left upper arm and left thorax wall, respectively, 8
years after the high-dose therapy, both not in irradiated areas.
Another melanoma was seen in a patient with germ cell cancer,
and a basal cell carcinoma of the mouth was diagnosed in a breast
cancer patient 5 and 4 years after treatment, respectively. The only
other solid neoplasm was a mixed mu ¨llerian tumour of the ovary, 3
years after high-dose therapy.
Two breast cancer patients developed myelodysplasia (MDS).
One patient was diagnosed with MDS and had retrospectively
already signs of MDS in the bone marrow before the start of
chemotherapy. She died of brain metastases of breast cancer, 1
month after developing bone marrow failure due to MDS (8
months after transplant). The second patient developed bone
marrow failure almost 8 years after high-dose treatment and died
of bone marrow failure due to transformation to an acute
leukaemia without having a relapse. The bone marrow of this
patient showed multiple cytogenic abnormalities (deletion of 3q,
13q, 20q and addition of 5q and 18q).
DISCUSSION
We have analysed the clinical data of 100 consecutive patients who
underwent HD-CT with CTC. The objective of this analysis was to
describe the early and late toxicities of this regimen, which is
similar to but not identical with the CTCb (STAMP-V) regimen
described by Antman et al (1992).
Since the introduction of PBPC-Tx myelosuppression has ceased
to be dose-limiting. In patients who also received G-CSF after
transplant, the median time to a neutrophil count of X0.5 10
9l
 1
was 10 days after transplant and the time to platelet transfusion
independence was 13 days after transplant. The brief but profound
bone marrow suppression is not without hazards, however, and
one of the patients in this series died as a result of bleeding and
sepsis. A toxic death rate of 1% is in line with the findings in most
recent studies of HD-CT. It is also consistent with the finding of
the European Bone Marrow Transplantation registry that a toxic
death rate of 1% has been stable in the adjuvant chemotherapy
setting for breast cancer since 1995 (Rosti and Ferrante, 2001).
The acute toxicity of CTC is substantial but consistently
reversible. We have previously shown that CTC courses can be
repeated and we have in fact administered three subsequent CTC
courses in patients with breast cancer or germ cell cancer
Table 6 Long-term toxicity
Germ cell Breast cancer Other All patients
No. of patients 8 90 2 100
Ototoxicity
Symptomatic hearing loss 1
High frequency 0 1 0 1
Conversation 0 0 0 0
Intermittent tinnitus 0 2 0 2
Neuropathy 9
Slight sensory 2
a 507
Moderate sensory 0 2 0 2
Slight motor 0 0 0 0
Cardiotoxicity 3
Myocardial infarction 1 0 0 1
Decline of LV function 0 2 0 2
Nephrotoxicity
b
Persisting creatinine elevation 3
c 407
Pulmonary toxicity
Radiation pneumonitis
d 01 1 0 20
Pleural effusion (transient) 0 6 0 6
Other 1 2 0 3
aLV function¼left ventricular function. One patient already had neuropathy before start of the CTC protocol.
bDefined as
creatinine 4130mmoll
 1.
cThree patients already had an elevated creatinine before start of the CTC regimen. One patient
needed a kidney transplantation.
dRadiation pneumonitis responsive to steroids. Bold values denote the total number of
patients in each category.
Table 7 Second neoplasms
All patients
No. of patients 100
Skin tumours 4
Melanoma 2
Basal cell carcinoma 1
Squamous cell carcinoma 1
Mixed mu ¨llerian tumour of ovary 1
Cervical polyp of uterus 1
Tubular adenoma of colon 1
Myelodysplasia 2
Bold values denote the total number of patients under each category.
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l(Rodenhuis et al, 1996). Patients who receive more than a single
course of CTC may, however, develop major organ toxicity,
including severe haemorrhagic cystitis, veno-occlusive disease and
haemolytic uraemic syndrome. In addition, in some patients
irreversible alopecia may occur. All these problems were never
seen in patients who received only a single CTC course, with the
exception of the single patient with a very mild haemorrhagic
cystitis seen in this series (Table 4).
The supportive care of CTC has been changed throughout the
years and we saw the most toxicity in the first courses. Whether
this is due to the better supportive care or the increasing
experience with HD-CT is unsolved. It would be interesting to
compare our results with toxicity data of other centres, but up till
now, these data are not available.
An important concern in patients who receive high-dose
alkylating therapy is DNA damage of nontumour cells, which
may in itself lead to second tumours. In this series of 100 patients,
we have observed two cases of myelodysplastic syndrome, one of
which was already present before the start of HD-CT. The early
MDS may be the result of epirubicin exposure, as seen in the
Scandinavian trial (Bergh et al, 2000), but in the second patient the
interval was too long for a relation with topo-isomerase II
inhibitors. There were also four skin cancers (two of which were
melanomas) and a mixed mu ¨llerian tumour of the ovary (Table 7).
Clearly, even a median follow-up of 7 years is insufficient to
estimate reliably the number of second solid tumours that may be
induced by the treatment.
A second long-term toxicity that we have recently described is
impairment of cognitive function (van Dam et al, 1998). This type
of toxicity has been associated with a single high-dose course CTC
and many of the patients reported here have contributed to these
studies (Schagen et al, 2001). The severity of symptoms associated
with these abnormalities at neuropsychological testing is, however,
generally mild. Current work focuses on the reversibility of the
testing abnormalities after several years.
A variety of high-dose regimens for solid tumours have
been reported to date. Some of these have been used in larger
randomised studies. The latter regimens can arguably be divided
into three categories: (i) the STAMP-I regimen, consisting
of cisplatin, BCNU and cyclophosphamide; (ii) the CTCb-like
regimens, which are based on cyclophosphamide and thiotepa
with or without carboplatin; and (iii) the mitoxantrone-based
regimens. We believe that the first category, the STAMP-I regimen,
is too toxic for routine use. The two studies (Peters et al, 1993;
Nikcevich et al, 2002) that employed this carmustine-based
combination reported high toxic death rates due to organ
toxicity, mainly interstitial pneumonitis. Even very experienced
centres that optimally exploit corticosteroids at the earliest sign of
pulmonary symptoms report a 5% toxic death rate (Antman et al,
1992).
Regimens of the third category, employing mitoxantrone, may
have acceptable toxicity and appear to be effective in breast cancer,
at least in preliminary analyses of randomised studies (Roche et al,
2001). It will be important to evaluate the long-term cardiotoxicity
of high-dose mitoxantrone, particularly in patients who have
previously received anthracyclines for breast cancer and who
subsequently undergo radiation therapy of the chest wall, which
includes the myocardium.
The CTCb-like regimens have been reported to be well-tolerated.
We have extensively studied the complicated pharmacokinetics of
this combination and have shown that the activation route of the
prodrug cyclophosphamide is effectively inhibited in the presence
of thiotepa. In theory, a continuous infusion of thiotepa could lead
to less active second metabolites, to less toxicity and possibly even
less efficacy of the cyclophosphamide–thiotepa combination
(Anderson et al, 1996; Peters et al, 1999; Teicher et al, 1999;
Huitema et al, 2000). In the classic STAMP-V or CTCb regimen,
cyclophosphamide and thiotepa are also being given as continuous
infusions, but this is different in the CTC regimen reported in this
paper. Perhaps this difference could account for the possibly
somewhat higher acute toxicity of CTC in comparison to CTCb.
This difference could, of course, also arise from the substantially
higher carboplatin dose in the CTC regimen. We have not been
able to administer CTC on an outpatient basis, mainly because of
nausea and vomiting. It is interesting that this type of toxicity is
much less pronounced when the dose of CTC is decreased by one-
third (Schrama et al, 2001). With such a dose reduction,
management of the aplastic phase outside the hospital becomes
feasible (Westermann et al, 1999). This illustrates that a relatively
minor difference in drug exposure can significantly affect the
tolerance of the regimen.
At this point in time, the future of HD-CT in the curative
treatment of solid tumours remains unclear. Over 3000 patients
with high-risk breast cancer have now been treated in randomised
studies and most of these studies show a modest benefit for the
high-dose arm in preliminary analyses. It is therefore likely that
certain individual tumours that cannot be cured by standard-dose
chemotherapy may sometimes be eradicated by high-dose therapy.
Since the latter treatment modality is toxic and expensive, the
ability to select tumours specifically for this treatment modality
would clearly be extremely useful. The recent development of
messenger RNA expression profiling (Van‘t Veer et al, 2002) has
raised hope that this technique could be used to test breast cancers
and other malignancies for important biological characteristics
such as alkylating agent sensitivity.
At the same time, efforts are continuing to decrease the toxi
city of HD-CT. We have recently developed assays that allow us to
analyse the pharmacokinetics and pharmacodynamics of the three
high-dose agents in the CTC regimen, including the major
metabolites of cyclophosphamide. As expected, major differences
exist between patients in the AUCs of cyclophosphamide
metabolites, thiotepa and its major metabolite tepa. We and
others (Wolff et al, 1990; Huitema et al, 2001) have observed that a
significant relation exists between the elevation of liver enzymes
and the combined thiotepa and tepa AUCs. In addition, it is mainly
the AUC of thiotepa and tepa that is associated with mucositis
(Hussein et al, 1996; Przepiorka et al, 1995. We are currently
employing the strategy of therapeutic drug monitoring, in which
pharmacokinetic measurements on the first day of administration
of CTC are used to determine the dosage of the three agents on
days 3 and 4. In this way, it is possible to prevent excessive
exposure to drugs or their metabolites in some patients and to
increase exposure in patients with unexpectedly rapid drug
disposition (Huitema et al, 2001, 2002). It remains to be shown,
however, that such a fine tuning of dose leads to less toxicity,
improved efficacy, or both.
The precise role for high-dose alkylating chemotherapy in solid
tumours is now gradually being defined. We believe that the CTC
regimen described in this paper is a suitable combination to be
further tested in randomised clinical trials.
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